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Abstract
BACKGROUND: Chronic kidney disease (CKD) is classified as a multifactorial disease as a combination of 
genetic and environmental factors that affect the onset and progression of end-stage renal disease (ESRD). In 
the last decades are recognized that inflammation, where the critical modulator is cytokines, can occur before the 
onset of kidney disease and can be a causative factor in the development of CKD. Interleukin (IL)-6 has several 
polymorphisms in the promoter region, such as 174 G-C, 634 C-G, 572 G-C, and 597 G-A. G/C single nucleotide 
polymorphism of the IL-6 gene at position 174 in the promoter region is reported to affect the level of IL-6 expression. 
Unfortunately, there is a lack of data about the genotype frequencies of -174 G/C IL-6 promoter gene polymorphism 
in Indonesian with ESRD.
AIM: This study aimed to analyze whether −174 G/C IL-6 promoter gene polymorphism influences the concentration 
of IL-6 in ESRD patients with dialysis in Indonesia.
METHODS: We recruited 95 outpatients who were undergoing regular hemodialysis for ≥3 months at the Rasyida 
Renal Hospital, Medan, in this cross-sectional study. IL-6 genotype polymorphism was analyzed using the polymerase 
chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The enzyme-linked immunosorbent 
assay method was performed to assess the quantitative IL-6 serum.
RESULTS: PCR-RFLP examination showed the frequency distribution of the IL-6 genotype -174 G/C gene; 72 
(75.8%) respondents had GG genotypes; 22.1% of respondents had the CG genotype, and (2.1%) had the CC 
genotypes. Patients with the CC genotype were statistically significant to have higher IL-6 concentration compared to 
other genotypes (p < 0.001). Likewise, with diabetic patients, statistics showed higher IL-6 concentration compared 
to non-diabetics patients (p < 0.001).
CONCLUSION: This is the first study showing that -174 G/C IL-6 promoter gene polymorphism influences the IL-6 
concentrations in ESRD patients with dialysis in Indonesia. Multicenter studies are needed to validate these findings.
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Introduction
The number of patients suffering from chronic 
kidney disease (CKD) is now increasing in Indonesia. 
This is a medical, social, and economic problem for 
patients and their families [1]. CKD is classified as 
a multifactorial disease, which is a combination of 
genetic and environmental factors that affect the onset 
and progression to end-stage renal disease (ESRD). 
Recent years were recognized that inflammation can 
occur before the onset of kidney disease and can be 
a causative factor in the development of CKD [2]. An 
important modulator in inflammation is cytokines. 
Increased levels of pro-inflammatory cytokines can be a 
sign of CKD. Cytokines play an intricate role in the center 
of coordination in gene activation and suppression. The 
expression of related factors to inflammatory response 
is thought to be governed by genetic variations [3].
Variability between individuals in the 
development of CKD may be due to polymorphisms 
of various genes that encode cytokines and other 
inflammatory mediators [4]. These polymorphisms have 
been found in several studies that are associated with 
inflammatory and autoimmune disorders [5].
Interleukin 6 (IL-6) is a cytokine with both 
pros- and anti-inflammatory properties. It is a 21-kDa 
glycoprotein that is produced by numerous types of cells. 
The human IL-6 gene is located on chromosome 7p21 
and consists of five exons and four introns. IL-6 gene has 
several polymorphisms in the promoter region; 174 GC, 
634 CG, 572 GC, and 597 GA [3]. The most frequently 
studied polymorphism is single nucleotide polymorphism 
G/C at position 174 in the promoter region, which has been 
reported affecting the level of IL-6 expression [3], [5]. This 
study aims to investigate whether the polymorphism of the 
IL-6 -174 G/C promoter gene influences the concentration 
of IL-6 in ESRD patients with dialysis in Indonesia.
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Methods
Selection and description of participants
Ninety-five outpatients undergoing regular 
hemodialysis in the Rasyida Renal Hospital, Medan 
were included in this cross-sectional study after written 
informed consent was obtained from each subject. Data 
were collected from March to September 2019. Patients 
with an age of younger than 18 years, undergoing 
hemodialysis for <3 months, had liver disease, active 
infections, and malignancies were excluded from the 
study. The study was approved by the Health Research 
Ethical Committee of Medical School of Universitas 
Sumatera Utara/H. Adam Malik General Hospital, no. 283/
TGL/KEPK FKUSU-RSUP HAM/2019. All procedures in 
the protocol of this research were performed according 
to the guidelines of the Declaration of Helsinki.
Technical information
This study uses medical records and interview 
methods to assess socio-demographic characteristics 
(e.g., age, sex, diabetes mellitus [DM], hypertension, 
liver disease, malignancy, and duration of hemodialysis). 
Height in square meters and weight in kilograms were 
measured to calculate body mass index (BMI).
Venous blood samples after overnight fasting 
were collected in plain, ethylenediaminetetraacetic 
acid and citrate added tubes. The samples were either 
analyzed immediately or stored at −20 for the −174 G/C 
test. Routine laboratory methods analyzed calcium and 
phosphate.
IL-6 in serum was measured with an enzyme-
linked immunosorbent assay (ELISA) method using 
commercial kits (Qayee Bio Vendor IL-6 ELISA, 
Shanghai). The DNA extraction was examined by 
polymerase chain reaction (PCR) technique (Esco Swift 
TM Maxi Thermal Cycler, Singapore). DNA extracted 
from blood leukocytes from the whole blood taken from 
the purity and concentration of genomic DNA extract was 
determined using a spectrophotometer 1000 nanodrop 
Thermo Scientific (Thermo Fisher Scientific, USA). The 
PCR- restriction fragment length polymorphism (RFLP) 
technique was used to detect the polymorphism of the 
IL-6 -174 G/C promoter gene.
Statistical analysis
Statistical analysis was performed with 
SPSS software version 22.0 for Windows (SPSS, 
Chicago, IL, USA). Normal distribution was tested 
using the Kolmogorov–Smirnov test. Descriptive data 
for all variables were expressed as mean ± standard 
deviation (SD), median, and range for continuous 
data or percent of the group (n) for categorical data. 
An independent t-test was used to compare serum 
IL-6 levels among patient characteristics. Genotype 
frequency and other characteristics of hemodialysis 
patients between the high and low concentrations 
of IL-6 were compared using the Chi-square test or 
Fisher’s exact test if required. Prevalence ratios and 
their 95% confidence intervals were computed to 
identify the high concentration risk of IL-6 associated 
with the presence of the C allele. Comparisons were 
considered significant when (p < 0.05).
Results
Characteristics of ESRD patients with 
dialysis
Most of the patients were male, 53 (55.8%) with 
the range of age was 22–79 years and have undergone 
hemodialysis for 43–676 months. The mean ± SD of the 
BMI was 24.03 ± 4.30 kg/m2.
On laboratory examination, the mean ± SD of 
calcium concentration, phosphate concentration and 
calcium phosphate multiplication were 9.72 ± 0.74 
mg/dL, 5.43 ± 0.64 mg/dL, and 52.98 ± 9.08 mg2/dL2. 
Through the ELISA method, the median IL-6 level was 
70.1 pg/ml (range 25.4–898.0) with mean ± SD was 
97.95 ± 117.93 pg/ml. PCR-RFLP got the frequency 
distribution of genotypes −174G/C IL-6 gene; 72 
patients (75.8%) had the GG genotype; 21 patients 
(22.1%) had the CG genotype; and two patients (2.1%) 
had the CC genotype.
Table 1: Hemodialysis patient characteristic based on IL-6 level
Variable IL-6 concentration p PR 95% CI
High Low
Age (years)
<60 20 (37.0) 34 (63.0) 0.43 1.16 0.81–1.65
≥60 12 (29.3) 29 (70.7)
Duration of hemodialysis (months)
<60 13 (34.2) 25 (65.8) 0.93 1.02 0.61–1.72
≥60 19 (33.3) 38 (66.7)
Diabetes mellitus
No 18 (24.3) 56 (75.7) <0.001 3.94 1.77–8.78
Yes 14 (66.7) 7 (33.3)
BMI (kg/m2)
Underweight-normal 26 (38.2) 42 (61.8) 0.14 1.22 0.96–1.55
Overweight-obese 6 (22.2) 21 (77.8)
Calcium level (mg/dL),
≤9.5 12 (31.6) 26 (68.4) 0.72 1.06 0.76–1.50
>9.5 20 (35.1) 37 (64.9)
Phosphate level (mg/dL),
≤5.5 16 (32.0) 34 (68.0) 0.71 1.09 0.70–1.68
>5.5 16 (35.6) 29 (64.4)
Polymorphism, n (%)
Genotype GG 9 (12.5) 63 (87.5) <0.001 7.10 3.97–12.71
Genotype GC + CC 23 (100.0) 0 (0.00)
IL: Interleukin, BMI: Body mass index.
The relationship of various factors with 
IL-6 levels
A receiver operating characteristic curve was 
used to determine the cutoff value of IL-6 concentration. 
Based on the area under the curve, the IL-6 cutoff value 
was 81.1 pg/ml. The characteristics of hemodialysis 
patients based on the IL-6 concentration category can 
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be seen in Table 1. Statistical tests significantly showed 
that the group of patients with high IL-6 concentration 
(>81.1 pg/ml) was dominated by patients suffering from 
DM (66.7%) (p < 0.001). From this table, we also could 
conclude that high IL-6 levels are more likely to be 
experienced 3.94 times (95% CI: 1.77–8.78) by patients 
suffering from DM. Besides, based on polymorphisms in 
the IL-6 gene, it can be seen that all patients with C alleles 
(100%) had a high concentration of IL-6 compared to other 
groups (p < 0.001).
Table 2 showed that patients with the CC 
genotype were statistically significant to have higher 
IL-6 concentration compared to other genotypes 
(p < 0.001). Likewise, with diabetic patients, statistics 
showed higher IL-6 levels compared to non-diabetics 
patients (p < 0.001).
Discussion
Increased levels of IL-6 in patients with 
ESRD are associated with decreased kidney function, 
persistent infection, factors associated with dialysis, 
and genetic factors [6]. Genetic factors have influenced 
the incidence of ESRD. A research conducted by Aker 
et al. has proved it. His research showed that there is 
a correlation between IL-6 gene polymorphisms and 
ESRD. Aker also stated that patients with CC genotype 
had a higher risk of death than other genotypes [7]. 
Research conducted by Ng et al. regarding the 
relationship between IL-6 haplotype on human 
chromosomes and risk factors for kidney dysfunction 
in patients with type 2 DM found that IL-6 −174 G/C 
gene polymorphisms are associated with ESRD 
risk [8]. Ranganath et al., in his research, also showed 
the same thing that the IL-6 gene polymorphism was 
associated with ESRD risk. His research showed that 
IL-6 levels increased in ESRD patients, which was a 
37.5-fold increase compared to the control group in the 
CC genotype, 4.4 times in the GC genotype, and 0.18 
times in the GG genotype [9].
This study shows different results from studies 
conducted by Buckham et al. [10] and Kandil et al. [11] 
Kandil et al. found no difference in IL-6 levels in ESRD 
patients with patients who were not ESRD (p = 0.61) 11. 
Research conducted by Buchkam et al. in Caucasian 
tribes in various countries showed that GC genotype 
frequency (48%) higher than the GG genotype (34.8%), 
then followed by the CC genotype (17.2%). The same 
study conducted by Kandil et al. in Egypt showed that the 
GG genotype (77.1%) was higher than the GC genotype 
(20%) and the CC genotype (2.9%) [11]. A study 
conducted by Ng et al. in the United States also found 
the same results. They showed that the GG genotype 
(54.6%) was higher than the GC genotype (29.6%) 
and the CC genotype (15.8%) [8]. Likewise, research 
conducted by Ranganath et al. in India showed that the 
GG genotype (62.8%) was higher than the GC genotype 
(31%), followed by the CC genotype (6.2%) [9]. The 
difference in genotype frequency is possible for various 
reasons, such as demographic factors of the subject, 
lifestyle differences, and the number of study samples.
This study shows that patients with the CC 
genotype (x̄ = 656) statistically have significantly 
higher levels of IL-6 than other genotypes such 
as CG (x̄ = 167.4952) and GG (x̄ = 62.1653). The 
previous studies have suggested that IL-6-174 allele 
C polymorphism is associated with increased levels of 
IL-6 in the general population. Patients with IL-6 -174 
allele C have higher serum IL-6 levels so that they may 
have a worse response to treatment [12].
Statistics in this study show that IL-6 levels 
are higher in diabetic patients than in non-diabetics 
(p < 0.001). Su et al. further shows the correlation 
between IL-6 and autoimmune diabetes. Likewise in 
type 2 diabetes, IL-6 levels increase and are associated 
with the development of atherosclerosis [13].
Research conducted by Beberashviilii 
regarding the relationship between IL-6 and the state 
of nutritional status proves that there is no relationship 
between nutritional factors and increased levels of IL-6 
[14]. This statement is in line with the results obtained 
from this study, where the increase in IL-6 levels is not 
higher in overweight-obese patients (22.2%) compared 
to underweight-normal patients (38.2%).
Conclusion
This study shows that there is an influence of the 
174 G/C IL-6 gene polymorphism on IL-6 concentrations 
in ESRD patients with dialysis in Indonesia.
Table 2: Comparison of IL-6 level based on hemodialysis patient 
characteristic
Variable IL-6 concentration p
Mean Median
Polymorphism
CC 656 656.0 <0.001
CG 167.5 118.0
GG 62.2 62.1
Age (years)
<60 95.9 71.3 0.4
≥60 100.6 69.9
Duration of hemodialysis (months)
<60 82.3 64.2 0.9
≥60 108.4 71.3
Diabetes mellitus
No 94.7 65.4 <0.001
Yes 109.3 92.5
Classification of BMI
Underweight-normal 106.1 71.8 0.1
Overweight-obese 77.5 63.1
Calcium concentration (mg/dL)
≤9.5 81.6 70.7 0.7
>9.5 108.9 69.9
Phosphate concentration (mg/dL)
≤5.5 109.9 70.0 0.7
>5.5 84.7 71.4
IL: Interleukin, BMI: Body mass index.
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